Evidence map›Paper›PMID 26239450›Full record

ReviewJournal of clinical medicine2015

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV.

Ramya Kollipara, Erfon Ekhlassi, Christopher Downing, Jacqueline Guidry, Michael Lee, Stephen K Tyring

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03625960 (Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03625960 phase4completednot on this map

Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts

TypeinterventionalSponsorWayne State UniversityRan2006 to 2007Enrolled12ConditionsWart, GenitalArmsCantharidin, Trichloroacetic Acid
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. The efficacy of intralesional vitamin D3 injection in the treatment of cutaneous warts: A clinical therapeutic trial study.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2023
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. HPV Infections-Classification, Pathogenesis, and Potential New Therapies.International journal of molecular sciences · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ramya KolliparaCenter for Clinical Studies, Houston 77004, TX, USA. rkollipara@ccstexas.com.
Erfon EkhlassiDepartment of Dermatology, the University of Texas Health Science Center at Houston, Houston 77030, TX, USA. Erfon.Ekhlassi@uth.tmc.edu.
Christopher DowningCenter for Clinical Studies, Houston 77004, TX, USA. cdowning@ccstexas.com.
Jacqueline GuidryCenter for Clinical Studies, Houston 77004, TX, USA. jguidry@ccstexas.com.
Michael LeeCenter for Clinical Studies, Houston 77004, TX, USA. mlee@ccstexas.com.
Stephen K TyringCenter for Clinical Studies, Houston 77004, TX, USA. Erfon.Ekhlassi@uth.tmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

Indexed as

condylomaHPVpharmacotherapytreatmentwarts

Identifiers

PMID26239450
PMCPMC4470201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.